Kalydeco ivacaftor regulatory update

Australia's Therapeutic Goods Administration ( TGA) approved Kalydeco ivacaftor from Vertex to treat cystic fibrosis in patients >=6 years who have at least 1 copy of the G551D mutation in the CF tran...